We are live on ! Find out more
STRO icon

Sutro Biopharma
STRO

122 hedge funds and large institutions have $118M invested in Sutro Biopharma in 2024 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 41 increasing their positions, 35 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

263% more call options, than puts

Call options by funds: $243K | Put options by funds: $67K

17% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 35

0.12% more ownership

Funds ownership: 7.63% → 7.75% (+0.12%)

6% less funds holding

Funds holding: 130 → 122 (-8)

23% less first-time investments, than exits

New positions opened: 23 | Existing positions closed: 30

46% less capital invested

Capital invested by funds: $216M → $118M (-$98.8M)

Holders
122
Holders Change
-8
Holders Change %
-6.15%
% of All Funds
1.61%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.03%
New
23
Increased
41
Reduced
35
Closed
30
Calls
$243K
Puts
$67K
Net Calls
+$176K
Net Calls Change
+$29K

Top Buyers

1
VPC
Vestal Point Capital
New York
+$7.85M
2
KCM
Kynam Capital Management
New Jersey
+$4.81M
3
Morgan Stanley
Morgan Stanley
New York
+$3.8M
4
BlackRock
BlackRock
New York
+$1.76M
5
Prudential Financial
Prudential Financial
New Jersey
+$1.3M

Top Sellers

1
Millennium Management
Millennium Management
New York
-$4.96M
2
Baillie Gifford & Co
Baillie Gifford & Co
United Kingdom
-$4.49M
3
EP
Eversept Partners
New York
-$3.5M
4
Bank of Montreal
Bank of Montreal
Ontario, Canada
-$2.85M
5
Arrowstreet Capital
Arrowstreet Capital
Massachusetts
-$2.55M
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$14M +$1.76M +57,707 +8%
SCM
2
Suvretta Capital Management
New York
$13.7M +$840K +27,500 +4%
Vanguard Group
3
Vanguard Group
Pennsylvania
$7.74M +$41K +1,343 +0.3%
KCM
4
Kynam Capital Management
New Jersey
$6.7M +$4.81M +157,500 +76%
MC
5
Merck & Co
New Jersey
$5.01M +$8.31M +272,351 New
VPC
6
Vestal Point Capital
New York
$4.73M +$7.85M +257,000 New
Citadel Advisors
7
Citadel Advisors
Florida
$4.52M +$1.01M +33,200 +16%
Point72 Asset Management
8
Point72 Asset Management
Connecticut
$4.04M -$2.44M -79,991 -27%
SB
9
Samsara BioCapital
California
$4.04M – – –
MB
10
MPM BioImpact
Massachusetts
$3.97M -$2.05M -67,200 -24%
Adage Capital Partners
11
Adage Capital Partners
Massachusetts
$3.68M -$764K -25,013 -11%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$3.41M -$8.97K -294 -0.2%
Acadian Asset Management
13
Acadian Asset Management
Massachusetts
$3.22M +$434K +14,206 +9%
PHP
14
Parkman Healthcare Partners
Connecticut
$3.18M +$36K +1,180 +0.7%
Goldman Sachs
15
Goldman Sachs
New York
$3.15M -$97.2K -3,185 -2%
State Street
16
State Street
Massachusetts
$3.13M +$167K +5,471 +3%
Morgan Stanley
17
Morgan Stanley
New York
$2.8M +$3.8M +124,605 +455%
N
18
Nuveen
North Carolina
$2.44M +$379K +12,416 +10%
Dimensional Fund Advisors
19
Dimensional Fund Advisors
Texas
$2.09M +$477K +15,614 +16%
Renaissance Technologies
20
Renaissance Technologies
New York
$1.87M +$571K +18,711 +23%
Jacobs Levy Equity Management
21
Jacobs Levy Equity Management
New Jersey
$1.58M +$115K +3,762 +5%
EP
22
Eversept Partners
New York
$1.28M -$3.5M -114,758 -62%
Northern Trust
23
Northern Trust
Illinois
$1.17M +$44.2K +1,449 +2%
Two Sigma Advisers
24
Two Sigma Advisers
New York
$1.01M -$132K -4,310 -7%
Prudential Financial
25
Prudential Financial
New Jersey
$1.01M +$1.3M +42,610 +351%
1
2 3 4 5

STRO Hedge Fund Activity: Q4 2024 in Review

122 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Sutro Biopharma (STRO) for Q4 2024, worth a combined $118M — down 46% from $216M a quarter earlier.

Sellers outnumbered buyers: 30 funds closed out of STRO and 23 opened new positions — a net loss of 7 holders — while 35 trimmed existing stakes and 41 added.

The largest buyer was Vestal Point Capital, opening a new position worth an estimated $7.85M. The largest seller was Millennium Management, cutting an estimated $4.96M.

  • 122 institutional investors held Sutro Biopharma (STRO) as of Q4 2024, down from 130 in Q3 2024.
  • Funds reported $118M of Sutro Biopharma stock for Q4 2024, down 46% quarter-over-quarter.
  • 23 funds opened new Sutro Biopharma positions in Q4 2024 and 30 closed out, a net change of -7 holders.
  • The largest Sutro Biopharma buyer in Q4 2024 was Vestal Point Capital, an estimated $7.85M added.
  • The largest Sutro Biopharma seller in Q4 2024 was Millennium Management, an estimated $4.96M sold.

Based on aggregated 13F filings for Q4 2024.